Drugs for HER2-positive Breast Cancer
(Sprache: Englisch)
Growth factor receptors have long been known to drive malignant transformation and cancer progression. The epidermal growth factor receptor (EGFR, ErbB, HER) system is likely the best described membrane receptor tyrosine kinase family in malignant tumors....
Leider schon ausverkauft
versandkostenfrei
Buch
186.99 €
- Lastschrift, Kreditkarte, Paypal, Rechnung
- Kostenlose Rücksendung
- Ratenzahlung möglich
Produktdetails
Produktinformationen zu „Drugs for HER2-positive Breast Cancer “
Klappentext zu „Drugs for HER2-positive Breast Cancer “
Growth factor receptors have long been known to drive malignant transformation and cancer progression. The epidermal growth factor receptor (EGFR, ErbB, HER) system is likely the best described membrane receptor tyrosine kinase family in malignant tumors. With implementation of the growth-inhibitory anti-HER-2 antibody trastuzumab (Herceptin) for the treatment of HER-2-positive advanced metastatic breast cancer, a new era has dawned in the therapy of this malignant disease. Unfortunately, trastuzumab-sensitive cancers invariably develop resistance to the antibody after some time. Recent clinical studies have revealed that these refractory tumors are still responsive to inhibition of the HER receptor family using dual HER-1/-2 inhibitors such as lapatinib (Tykerb/Tyverb). Moreover, a multiplicity of novel, improved irreversibly acting small molecular HER tyrosine kinase inhibitors are in the pipeline of many drug developing companies and are being evaluated in the clinical setting.Inhaltsverzeichnis zu „Drugs for HER2-positive Breast Cancer “
Drugs for HER-2-positive Breast Cancer: A Major Approval for Translational Cancer Research (Maria Sibilia, Christoph C. Zielinski, Rupert Bartsch, Thomas Grunt).- The EGFR/ErbB family in breast cancer: from signaling to therapy (Wolfgang J. Köstler and Yosef Yarden).- Trastuzumab as Adjuvant treatment for early stage HER-2 positive breast cancer (Rupert Bartsch and Guenther G. Steger).- Trastuzumab Resistance in breast cancer (Floriana Morgillo, Michele Orditura, Teresa Troiani, Erika Martinelli, Ferdinando De Vita, Fortunato Ciardiello).- Treatment with Trastuzumab beyond Progression (Gunter von Minckwitz and Cristina Pirvulescu).- Pertuzumab - a HER-2 dimerisation inhibitor - for the treatment of breast and other cancers (Giulia Bianchi and Luca Gianni).- Beyond trastuzumab: Second generation targeted therapies for HER-2-positive breast cancer (Flavio F. Solca, Guenther R. Adolf, Hilary Jones, Martina M. Uttenreuther-Fischer).
Bibliographische Angaben
- 2011, 110 Seiten, Maße: 16 x 24,1 cm, Gebunden, Englisch
- Herausgegeben:Sibilia, Maria; Zielinski, Christoph C.; Bartsch, Rupert; Grunt, Thomas W.
- Herausgegeben: Maria Sibilia, Thomas W. Grunt, Rupert Bartsch, Christoph C. Zielinski
- Verlag: Springer
- ISBN-10: 3034600933
- ISBN-13: 9783034600934
- Erscheinungsdatum: 07.01.2011
Sprache:
Englisch
Rezension zu „Drugs for HER2-positive Breast Cancer “
From the reviews:"This book takes readers on a journey from HER-2 signalling to therapeutic use of trastuzumab in the neoadjuvant, adjuvant and metastatic settings. ... It is a tour-de-force and should be essential reading for anyone setting out in the HER-2 research field. ... Overall, this small book covers the topic of HER-2 inhibition very well in a field that is rapidly changing." (S. W. Wong and R. M. Lowenthal, Inflammation Research, Vol. 61, 2012)
Kommentar zu "Drugs for HER2-positive Breast Cancer"
Schreiben Sie einen Kommentar zu "Drugs for HER2-positive Breast Cancer".
Kommentar verfassen